Novartis has received a FDA approval for its CAR-T treatment tisagenlecleucel, a first-ever cell therapy for a rare form of acute lymphoblastic leukemia. The US Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up … Continue reading Historic approval for Novartis